UY38958A - Agonista del receptor glp-1 y uso de este - Google Patents
Agonista del receptor glp-1 y uso de esteInfo
- Publication number
- UY38958A UY38958A UY0001038958A UY38958A UY38958A UY 38958 A UY38958 A UY 38958A UY 0001038958 A UY0001038958 A UY 0001038958A UY 38958 A UY38958 A UY 38958A UY 38958 A UY38958 A UY 38958A
- Authority
- UY
- Uruguay
- Prior art keywords
- glp
- compounds
- exhibit excellent
- receptor agonist
- receptor agonists
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title abstract 3
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000003287 optical effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- -1 isomers Chemical class 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen compuestos novedosos de la Fórmula Química 1, isómeros ópticos de los compuestos, y sales farmacéuticamente aceptables de los compuestos o los isómeros ópticos. Los compuestos, isómeros, y sales exhiben excelente actividad como agonistas del receptor GLP-1. En particular, estos, como agonistas del receptor GLP-1, exhiben una excelente tolerancia a la glucosa, por ende, tienen un gran potencial de ser usados como agentes terapéuticos para enfermedades metabólicas. Asimismo, exhiben una excelente seguridad farmacológica para los sistemas cardiovasculares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190146798 | 2019-11-15 | ||
| KR1020200022485A KR20210059584A (ko) | 2019-11-15 | 2020-02-24 | Glp-1 수용체 작용제 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38958A true UY38958A (es) | 2021-05-31 |
Family
ID=76145757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038958A UY38958A (es) | 2019-11-15 | 2020-11-13 | Agonista del receptor glp-1 y uso de este |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR20210059584A (es) |
| AR (1) | AR120458A1 (es) |
| TW (2) | TW202128658A (es) |
| UY (1) | UY38958A (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220152083A (ko) | 2021-05-07 | 2022-11-15 | 주식회사 엘지화학 | 가교구조 함유 올레핀고분자 다공지지체, 이를 포함하는 리튬 이차전지용 가교구조 함유 분리막, 이의 제조 방법, 및 상기 분리막을 구비한 리튬 이차전지 |
| AU2022335887A1 (en) * | 2021-08-30 | 2024-04-18 | Mindrank Ai Ltd. | Novel aryl ether substituted heterocyclic compound as glp1r agonist |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| TW202345815A (zh) * | 2022-03-25 | 2023-12-01 | 南韓商日東製藥股份有限公司 | Glp-1受體激動劑化合物之新穎鹽類、其製備方法以及包含其之醫藥組合物 |
| CN117362282A (zh) * | 2022-07-07 | 2024-01-09 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008012623A1 (en) * | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| PE20191501A1 (es) * | 2016-12-16 | 2019-10-22 | Pfizer | Agonistas receptores de glp-1 y sus usos de los mismos |
| CR20220178A (es) * | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
-
2020
- 2020-02-24 KR KR1020200022485A patent/KR20210059584A/ko unknown
- 2020-11-13 TW TW109139808A patent/TW202128658A/zh unknown
- 2020-11-13 TW TW109139809A patent/TWI786467B/zh active
- 2020-11-13 AR ARP200103146A patent/AR120458A1/es unknown
- 2020-11-13 UY UY0001038958A patent/UY38958A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202128658A (zh) | 2021-08-01 |
| AR120458A1 (es) | 2022-02-16 |
| TWI786467B (zh) | 2022-12-11 |
| TW202128659A (zh) | 2021-08-01 |
| KR20210059584A (ko) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022006183A2 (es) | Agonista del receptor glp-1 y uso de este | |
| UY38958A (es) | Agonista del receptor glp-1 y uso de este | |
| DOP2020000201A (es) | Compuestos heteroaril tetracíclicos | |
| UY37098A (es) | Moduladores de ror-gamma | |
| NI201900039A (es) | Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer | |
| CO2021012381A2 (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CL2009000780A1 (es) | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| AR110299A1 (es) | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico | |
| CL2016000495A1 (es) | Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades. | |
| AR108461A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| ECSP077323A (es) | Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias | |
| UY36416A (es) | 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de la mieloperoxidasa | |
| ECSP19062381A (es) | Moduladores del receptor de estrógeno | |
| AR061271A1 (es) | Antagonistas de cgrp | |
| CL2023003794A1 (es) | Agonista del receptor de glp-1 y composición y uso del mismo | |
| CO2019010029A2 (es) | Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer | |
| AR096338A1 (es) | (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles | |
| PE20211247A1 (es) | Sulfonas y sulfoxidos biciclicos y metodos de usos de los mismos | |
| UY38488A (es) | Derivados de pirazol y su uso en medicina | |
| AR107937A1 (es) | Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer | |
| CL2008001112A1 (es) | Usos de compuestos derivados de pirido[2,3-d]pirimidin-4-ona para tratar comezon o un trastorno relacionado con comezon; combinacion de los compuestos con otro farmaco; y uso de la combinacion para tratar la comezon o un trastorno relacionado con comezon. |